Larinate®

Ipca

Product category
  • Artesunate for injection

Therapeutic indication
  • Treatment of severe malaria caused by the parasite P. falciparum, to be followed by a full course of ACT

Dosing
  • At least 3 injections within 1 day during critical phase
  • 60mg
Efficacy
  • 92% survival vs 88% survival with quinine in African children

  • Coma duration, convulsions, and hypoglycaemia significantly lower with artesunate compared to quinine

Key features
  • Addressing supply challenges

  • Cost per disability-adjusted life year (DALY) averted: US$ 3.8
Challenges
  • Potential for delayed haemolytic anaemia

  • Continued use of quinine or artemether for injection
Status
  • WHO prequalification in 2018

  • Registered in 12 countries

Next milestone
  • Simplified injectable artesunate two vial to be developed for WHO prequalification review before 2020

  • Additional country registrations
MMV Project Director
  • Hans Rietveld